BACKGROUND: Sarcopenia, the age-related loss of muscle mass [defined as appendicular LBM/Height2 (aLBM/ht2) below peak value by>1SD], strength and function, is a major contributing factor to frailty in the elderly. MK-0773 is a selective androgen receptor modulator designed to improve muscle function while minimizing effects on other tissues. OBJECTIVES: The primary objective of this study was to demonstrate an improvement in muscle strength and lean body mass (LBM) in sarcopenic frail elderly women treated withMK-0773 relative to placebo. DESIGN: This was a randomized, double-blind, parallel-arm, placebo-controlled, multicenter, 6-month study. Participants were randomized in a 1:1 ratio to receive either MK-0773 50mg b.i.d. or placebo; all participants received Vitamin D and protein supplementation. SETTING: General community. PARTICIPANTS: 170 Women aged ≥65 with sarcopenia and moderate physical dysfunction. MEASUREMENTS: Dual energy X-ray absorptiometry, muscle strength and power, physical performance measures. RESULTS: Participants receiving MK-0773 showed a statistically significant increase in LBM from baseline at Month 6 vs. placebo (p<0.001). Participants receiving both MK-0773 and placebo showed a statistically significant increase in strength from baseline to Month 6, but the mean difference between the two groups was not significant (p=0.269). Both groups showed significant improvement from baseline at Month 6 in physical performance measures, but there were no statistically significant differences between participants receiving MK-0773 and placebo. A greater number of participants experienced elevated transaminases in the MK-0773 group vs. placebo, which resolved after discontinuation of study therapy. MK-0773 was generally well-tolerated with no evidence of androgenization. CONCLUSIONS: The MK-0773-induced increase in LBM did not translate to improvement in strength or function vs. placebo. The improvement of strength and physical function in the placebo group could be at least partly attributed to protein and vitamin D supplementation.
RCT Entities:
BACKGROUND:Sarcopenia, the age-related loss of muscle mass [defined as appendicular LBM/Height2 (aLBM/ht2) below peak value by>1SD], strength and function, is a major contributing factor to frailty in the elderly. MK-0773 is a selective androgen receptor modulator designed to improve muscle function while minimizing effects on other tissues. OBJECTIVES: The primary objective of this study was to demonstrate an improvement in muscle strength and lean body mass (LBM) in sarcopenic frail elderly women treated with MK-0773 relative to placebo. DESIGN: This was a randomized, double-blind, parallel-arm, placebo-controlled, multicenter, 6-month study. Participants were randomized in a 1:1 ratio to receive either MK-0773 50mg b.i.d. or placebo; all participants received Vitamin D and protein supplementation. SETTING: General community. PARTICIPANTS: 170 Women aged ≥65 with sarcopenia and moderate physical dysfunction. MEASUREMENTS: Dual energy X-ray absorptiometry, muscle strength and power, physical performance measures. RESULTS:Participants receiving MK-0773 showed a statistically significant increase in LBM from baseline at Month 6 vs. placebo (p<0.001). Participants receiving both MK-0773 and placebo showed a statistically significant increase in strength from baseline to Month 6, but the mean difference between the two groups was not significant (p=0.269). Both groups showed significant improvement from baseline at Month 6 in physical performance measures, but there were no statistically significant differences between participants receiving MK-0773 and placebo. A greater number of participants experienced elevated transaminases in the MK-0773 group vs. placebo, which resolved after discontinuation of study therapy. MK-0773 was generally well-tolerated with no evidence of androgenization. CONCLUSIONS: The MK-0773-induced increase in LBM did not translate to improvement in strength or function vs. placebo. The improvement of strength and physical function in the placebo group could be at least partly attributed to protein and vitamin D supplementation.
Authors: Christina Wang; Glenn Cunningham; Adrian Dobs; Ali Iranmanesh; Alvin M Matsumoto; Peter J Snyder; Thomas Weber; Nancy Berman; Laura Hull; Ronald S Swerdloff Journal: J Clin Endocrinol Metab Date: 2004-05 Impact factor: 5.958
Authors: V A Hughes; W R Frontera; M Wood; W J Evans; G E Dallal; R Roubenoff; M A Fiatarone Singh Journal: J Gerontol A Biol Sci Med Sci Date: 2001-05 Impact factor: 6.053
Authors: Roger A Fielding; Nathan K LeBrasseur; Anthony Cuoco; Jonathan Bean; Kelly Mizer; Maria A Fiatarone Singh Journal: J Am Geriatr Soc Date: 2002-04 Impact factor: 5.562
Authors: G Abellan van Kan; Y Rolland; S Andrieu; J Bauer; O Beauchet; M Bonnefoy; M Cesari; L M Donini; S Gillette Guyonnet; M Inzitari; F Nourhashemi; G Onder; P Ritz; A Salva; M Visser; B Vellas Journal: J Nutr Health Aging Date: 2009-12 Impact factor: 4.075
Authors: M Muscaritoli; S D Anker; J Argilés; Z Aversa; J M Bauer; G Biolo; Y Boirie; I Bosaeus; T Cederholm; P Costelli; K C Fearon; A Laviano; M Maggio; F Rossi Fanelli; S M Schneider; A Schols; C C Sieber Journal: Clin Nutr Date: 2010-01-08 Impact factor: 7.324
Authors: T Gagliano-Jucá; E R Tang; S Bhasin; K M Pencina; S Anderson; H Jara; Z Li; K Melamud; S L Coleman; A Aakil; R R Almeida; G Huang; T G Travison; T W Storer; S Basaria Journal: Andrology Date: 2017-07-13 Impact factor: 3.842
Authors: Richard V Clark; Ann C Walker; Susan Andrews; Philip Turnbull; Jeffrey A Wald; Mindy H Magee Journal: Br J Clin Pharmacol Date: 2017-06-10 Impact factor: 4.335
Authors: E Dent; J E Morley; A J Cruz-Jentoft; H Arai; S B Kritchevsky; J Guralnik; J M Bauer; M Pahor; B C Clark; M Cesari; J Ruiz; C C Sieber; M Aubertin-Leheudre; D L Waters; R Visvanathan; F Landi; D T Villareal; R Fielding; C W Won; O Theou; F C Martin; B Dong; J Woo; L Flicker; L Ferrucci; R A Merchant; L Cao; T Cederholm; S M L Ribeiro; L Rodríguez-Mañas; S D Anker; J Lundy; L M Gutiérrez Robledo; I Bautmans; I Aprahamian; J M G A Schols; M Izquierdo; B Vellas Journal: J Nutr Health Aging Date: 2018 Impact factor: 4.075